Get the Daily Brief
Latest Biotech News
ASAH1 drives venetoclax resistance in AML: sphingolipid metabolism implicated
A BMC Cancer study identified ASAH1 and its impact on sphingolipid metabolism as a key mediator of resistance to venetoclax in acute myeloid leukemia, especially in monocytic phenotypes. The...
NSUN7–m5C axis sustains glioblastoma stemness: RNA modification as therapeutic target
New research reveals NSUN7-mediated m5C modification of circNTRK2 sustains glioblastoma stem cell properties, supporting tumor maintenance and therapy resistance. The study shows NSUN7 alters RNA...
Simple outpatient risk score predicts gastric cancer: externally validated PRS
Researchers developed and externally validated a prediction risk score (PRS) for gastric cancer designed for outpatient settings. The model uses readily available clinical and demographic...
Tumor exosomes drive brain metastasis: miR‑221‑3p promotes breast cancer colonization of brain
A Journal of Translational Medicine study showed tumor-derived exosomal miR-221-3p enhances breast cancer metastasis to the brain by reprogramming the brain microenvironment and supporting tumor...
MEF2C reverses cisplatin resistance in ovarian cancer: apoptosis reactivated
A new investigation found that activating the transcription factor MEF2C triggers intrinsic apoptosis and reverses cisplatin resistance in ovarian cancer cells. The authors demonstrated...
Talazoparib benefits BRCA‑mutant metastatic disease: multicenter retrospective evidence
A multicenter retrospective study reported durable responses to talazoparib in patients with BRCA-mutant metastatic breast and ovarian cancers, reinforcing the PARP inhibitor’s activity beyond...
Eli Lilly hits $1 trillion — pharma milestone
Eli Lilly reached a $1 trillion market valuation, marking the first time a pharmaceutical company has crossed that threshold. The milestone reflects outsized investor enthusiasm for the company’s...
Avadel takeover battle... Alkermes and Lundbeck duel
Avadel Pharmaceuticals is the focus of an active bidding contest after agreeing to an acquisition by Alkermes; Copenhagen-based Lundbeck countered with a higher proposal. Avadel’s board declared...
Medicaid coverage for GLP‑1s varies widely — study
A cross‑sectional analysis found substantial variation across state Medicaid programs in coverage and prior‑authorization requirements for antiobesity GLP‑1 receptor agonists. The paper by...
Semaglutide slows kidney disease progression — trial data
A clinical study reported that semaglutide, a GLP‑1 receptor agonist, reduces progression of kidney disease in patients with type 2 diabetes and chronic kidney disease. Researchers Alemu,...
Tirzepatide maintains weight-loss and diabetes prevention at three years
Longitudinal data show tirzepatide preserves weight‑loss efficacy and reduces diabetes incidence over a three‑year follow‑up, according to a study in the Journal of General Internal Medicine. The...
CombiCoR‑Vax trial launches: immunotherapy plus chemo for refractory MSS mCRC
Investigators opened the CombiCoR‑Vax phase II trial testing a sequential combination of immunotherapy and chemotherapy in refractory microsatellite‑stable metastatic colorectal cancer (mCRC). The...
Prophylactic third‑party NK cells after HSCT: safety signals in AML
A BMC Cancer study evaluated prophylactic infusions of third‑party natural killer (NK) cells following hematopoietic stem cell transplantation (HSCT) for high‑risk acute myeloid leukemia....
Distinct CD4 memory T‑cell program linked to type 1 diabetes — Science Immunology
Researchers from the University of Pennsylvania and the HPAP Consortium identified a conserved transcriptional and epigenetic program in a subset of CD4 memory helper T cells associated with type...
Blood biomarkers track Alzheimer’s across cognitive stages — Nature Communications
A Nature Communications study validated blood biomarkers that correspond to Alzheimer’s disease progression across cognitive stages in community cohorts. The research identified plasma signatures...
Automated MRI system flags clinically significant prostate cancer
A Nature Communications paper described an automated MRI system that reliably identifies clinically significant prostate cancer, integrating image processing and machine learning to standardize...
Thermal one‑pot CRISPR: rapid on‑site viral surveillance
Researchers published a thermally programmed, one‑pot CRISPR assay in Nature Communications that integrates thermal control with CRISPR molecular recognition to enable rapid, sensitive viral...
Iambic: AI and automation shrink chemistry‑to‑clinic to two years
San Diego startup Iambic reported that physics‑informed algorithms combined with automated chemistry have shortened its chemistry‑to‑clinic timeline to roughly two years, according to a BioCentury...
Sydnexis setback highlights FDA opacity — CRL raises concerns
BioCentury reported that Sydnexis received a complete response letter (CRL), a regulatory setback that staff and commentators say underscores growing concerns about FDA transparency and shifting...
Biotech follow‑ons raise nearly $950M — markets stay open
On Nov. 21, four biotech companies—Nuvalent, Olema, Invivyd and Inhibikase—priced follow‑on equity offerings that collectively approached $950 million, according to BioCentury’s public equity...